# Quantum Biopharma Ltd.: overview QNTM · Nasdaq · CIK 1771885 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/qntm.md) · [Financials](/companies/qntm/financials.md) · [Filings](/companies/qntm/filings.md) · [Insiders](/companies/qntm/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | | Free cash flow | $m | [(20.7)](/filings/0001654954-24-004067.md) | [(28.4)](/filings/0001654954-25-003693.md) | [(10.8)](/filings/0001185185-26-001069.md) | [(6.9)](/filings/0001185185-26-001069.md) | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/qntm/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [AdvisorShares Investments LLC](/funds/1425930.md) | 2026-06-30 | $736.9k | 203,564 | | Added +94,973 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $175.0k | 48,355 | | Added +16,854 | | [Platform Technology Partners](/funds/1830817.md) | 2026-06-30 | $148.8k | 41,116 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $120.9k | 33,405 | | Added +26,168 | | [Steward Partners Investment Advisory, LLC](/funds/1723397.md) | 2026-06-30 | $100.9k | 27,881 | | Added +23,500 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $57.4k | 15,863 | | Unchanged | | [Marex Group Ltd](/funds/1997464.md) | 2026-06-30 | $48.6k | 13,436 | | Reduced −32 | | [Mariner, LLC](/funds/1373442.md) | 2026-06-30 | $36.2k | 10,000 | | Reduced −59 | | [LANARK FINANCIAL, INC.](/funds/791540.md) | 2026-06-30 | $25.3k | 7,000 | | New +7,000 | | [OSAIC HOLDINGS, INC.](/funds/1677044.md) | 2026-06-30 | $22.8k | 6,295 | | Reduced −80 | ## Recent filings [All 356 filings](/companies/qntm/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-08 | 12:00 ET | [6-K](/filings/0001171843-26-006529.md) | Report of a foreign private issuer, period 2026-10-08 | 0001171843-26-006529 | | 2026-10-06 | 10:00 ET | [6-K](/filings/0001171843-26-006429.md) | Report of a foreign private issuer, period 2026-10-06 | 0001171843-26-006429 | | 2026-09-24 | 12:00 ET | [6-K](/filings/0001171843-26-006203.md) | Report of a foreign private issuer, period 2026-09-24 | 0001171843-26-006203 | | 2026-09-17 | 19:12 ET | [6-K](/filings/0001185185-26-004098.md) | Report of a foreign private issuer, period 2026-09-17 | 0001185185-26-004098 | | 2026-09-17 | 12:00 ET | [6-K](/filings/0001171843-26-006084.md) | Report of a foreign private issuer, period 2026-09-17 | 0001171843-26-006084 | | 2026-09-15 | 12:00 ET | [6-K](/filings/0001171843-26-006047.md) | Report of a foreign private issuer, period 2026-09-15 | 0001171843-26-006047 | | 2026-09-02 | 00:28 ET | [6-K](/filings/0001185185-26-003794.md) | Report of a foreign private issuer, period 2026-09-01 | 0001185185-26-003794 | | 2026-08-14 | 11:00 ET | [6-K](/filings/0001171843-26-005524.md) | Report of a foreign private issuer, period 2026-08-14 | 0001171843-26-005524 | | 2026-08-13 | 20:06 ET | [6-K](/filings/0001185185-26-003497.md) | Report of a foreign private issuer, period 2026-06-30 | 0001185185-26-003497 | | 2026-08-10 | 11:00 ET | [6-K](/filings/0001171843-26-005370.md) | Report of a foreign private issuer, period 2026-08-10 | 0001171843-26-005370 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001185185-26-001069.md), filed Mar 26, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1771885 - Tickers: QNTM - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: A6 - Filer category: Non-accelerated filer
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.